Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.34 Insider Own12.45% Shs Outstand75.00M Perf Week0.52%
Market Cap145.50M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float65.66M Perf Month7.78%
Income-21.32M PEG- EPS next Q-0.07 Inst Own34.29% Short Float2.02% Perf Quarter79.63%
Sales0.00M P/S- EPS this Y78.44% Inst Trans0.84% Short Ratio2.25 Perf Half Y130.84%
Book/sh0.53 P/B3.67 EPS next Y-5.15% ROA-99.14% Short Interest1.32M Perf Year59.02%
Cash/sh0.13 P/C14.42 EPS next 5Y- ROE-114.72% 52W Range0.77 - 2.24 Perf YTD71.68%
Dividend Est.- P/FCF- EPS past 5Y-26.70% ROI-252.55% 52W High-13.39% Beta2.30
Dividend TTM- Quick Ratio4.23 Sales past 5Y0.00% Gross Margin- 52W Low151.95% ATR (14)0.18
Dividend Ex-Date- Current Ratio4.23 EPS Y/Y TTM-20.43% Oper. Margin0.00% RSI (14)54.72 Volatility9.70% 10.66%
Employees5 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q41.86% Payout- Rel Volume0.18 Prev Close1.96
Sales Surprise- EPS Surprise47.73% Sales Q/Q- EarningsMay 08 AMC Avg Volume587.69K Price1.94
SMA20-0.36% SMA5014.54% SMA20055.68% Trades Volume103,923 Change-1.02%
Date Action Analyst Rating Change Price Target Change
May-16-24Initiated Piper Sandler Overweight $4.50
May-30-24 06:11AM
May-22-24 08:50PM
May-20-24 12:00PM
May-14-24 12:00PM
May-08-24 11:56PM
04:06PM Loading…
May-02-24 07:31AM
Apr-01-24 07:30AM
Mar-21-24 01:53PM
Nov-09-23 04:15PM
Oct-31-23 09:00AM
Oct-24-23 12:30PM
Sep-27-23 09:00AM
02:19PM Loading…
Aug-10-23 02:19PM
Aug-09-23 04:10PM
Aug-01-23 07:30AM
Jun-13-23 01:34PM
Jun-03-23 08:27AM
May-10-23 04:39PM
Apr-24-23 12:01PM
Apr-18-23 10:15AM
Apr-04-23 12:00PM
Apr-03-23 07:30AM
Mar-22-23 05:08PM
Mar-15-23 07:30AM
Feb-13-23 08:52AM
Feb-10-23 01:36PM
Feb-07-23 12:21PM
07:30AM Loading…
Feb-06-23 07:30AM
Jan-31-23 07:30AM
Jan-09-23 07:30AM
Jan-04-23 07:30AM
Dec-08-22 07:30AM
Nov-29-22 07:30AM
Nov-27-22 07:36AM
Nov-21-22 09:11AM
Nov-09-22 04:14PM
Oct-20-22 07:30AM
Sep-27-22 11:41AM
Sep-06-22 12:50PM
Aug-11-22 04:01PM
Aug-02-22 10:49AM
Jul-05-22 09:22PM
May-15-22 10:12AM
May-11-22 04:01PM
May-05-22 07:30AM
Apr-11-22 07:30AM
Apr-06-22 07:30AM
Mar-30-22 04:33PM
Mar-23-22 04:01PM
Mar-08-22 06:12PM
Feb-22-22 07:30AM
Jan-05-22 04:01PM
Jan-04-22 07:30AM
Dec-10-21 11:11AM
Dec-09-21 06:00PM
Dec-06-21 04:45PM
Dec-02-21 04:01PM
Dec-01-21 06:30PM
Nov-19-21 09:00AM
Nov-01-21 04:02PM
Oct-27-21 07:30AM
Oct-22-21 04:05PM
Oct-20-21 04:57PM
Oct-19-21 07:14PM
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.